TY - PAT
T1 - F3-Peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
AU - Moreira, João Nuno
AU - Silva, Lígia Catarina
AU - Bimbo, Luis Maria
AU - Santos, Adriana Oliveira
AU - Pedroso Lima, Maria da Conceição
AU - Simões, Sérgio
PY - 2011/9/29
Y1 - 2011/9/29
N2 - The present invention relates to F3 -peptide targeted lipid-based nanoparticles, adequate to encapsulate and delivery- one or more nucleic acids, comprising; a) one or more nucleic acids; b) one or more cationic lipids; c) one or more non- cationic lipids; d) one or more poly (ethylene glycol) - derivatized lipids; and e) one or more coupled targeting ligands which bind to the nucleolin receptor. The nanoparticles according to the invention have a high loading capacity, ability to protect the encapsulated nucleic acid, a size below 250 ran and a charge close to neutrality, which are adequate features for intravenous administration. The nanoparticles of the present inventon have the ability to selectively delivery a siRNA to cancer cells and/or endothelial cells from angiogenic blood vessels leading to an effective silencing of a target gene. These nanoparticles are used for the treatment of angiogenesis- dependent diseases, namely cancer, inflammation, an auto-immune disease or an ocular disorder.
AB - The present invention relates to F3 -peptide targeted lipid-based nanoparticles, adequate to encapsulate and delivery- one or more nucleic acids, comprising; a) one or more nucleic acids; b) one or more cationic lipids; c) one or more non- cationic lipids; d) one or more poly (ethylene glycol) - derivatized lipids; and e) one or more coupled targeting ligands which bind to the nucleolin receptor. The nanoparticles according to the invention have a high loading capacity, ability to protect the encapsulated nucleic acid, a size below 250 ran and a charge close to neutrality, which are adequate features for intravenous administration. The nanoparticles of the present inventon have the ability to selectively delivery a siRNA to cancer cells and/or endothelial cells from angiogenic blood vessels leading to an effective silencing of a target gene. These nanoparticles are used for the treatment of angiogenesis- dependent diseases, namely cancer, inflammation, an auto-immune disease or an ocular disorder.
M3 - Patent
M1 - WO2011119058
Y2 - 2011/03/22
ER -